In 2026, as South Africa prepares to introduce lenacapavir, another HIV-prevention injection is fading from view: long-acting cabotegravir, known as CAB-LA in short. Both lenacapavir and CAB-LA consist of antiretroviral medication that prevents HIV-negative people from getting infected with HIV through sex, but the former is taken once every six months and the latter once […]
The post CAB-LA: Prevention jab that never had its moment…
Read More
About The Author
